BCDA
BioCardia, Inc.
$0.8800
+10.00%
$10.0M
No data for this timeframe.
Vol
Market Cap$10.0M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders8 funds
Inst. Value$397.6K
Inst. Activity1 buys / 0 sells
Insider Activity11B / 0S
Insider Net $$29.8K
SEC Reports12
Press Releases4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0000925741·Prev Close $0.8000
Recent Activity
Jun 12, 2026
SEC
BioCardia received a Nasdaq extension to October 7, 2026, to regain compliance with the $2.5 million minimum stockholder
8-K — Impact 5/10
Jun 9, 2026
Insider
Altman Peter bought 5,000 shares
President and CEO @ $0.8500 ($4.3K)
Jun 8, 2026
SEC
BioCardia reported Q1 2026 EPS of -$0.21, missing the consensus estimate of -$0.18 by 16.7%. The company also disclosed
PRESS-RELEASE — Impact 7/10
Jun 8, 2026
SEC
BioCardia raised $4.4 million via an at-the-market (ATM) offering, selling 3,509,604 shares at an average price of $1.27
8-K — Impact 6/10
Jun 8, 2026
earnings
BioCardia Announces $4.4 Million Financing
<p align="center"><strong>Net proceeds anticipated to extend cash runway into first quarter of 2027
May 20, 2026
Insider
Altman Peter bought 1,500 shares
President and CEO @ $0.9200 ($1.4K)
May 19, 2026
Insider
Altman Peter bought 200 shares
President and CEO @ $0.9500 ($190.00)
Inst.
VANGUARD GROUP INC — ADD
135,561 shares ($169.5K)
Price Targets
$15.50
+1661.4% upside
Strong Buy
Current $0.8800
Low $6.00
Median $15.50
High $25.00
2 analysts
$6.00
$25.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 9, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.19 ▼ -5.6% | $-0.19 — $-0.19 | 1 | |
| Next Q | $-0.18 ▼ -5.9% | $-0.18 — $-0.18 | 25% YoY | 1 |
| Current FY | $-0.76 ▼ -7.0% | $-0.76 — $-0.76 | 38% YoY | 1 |
| Next FY | $-0.60 ▼ -7.1% | $-0.60 — $-0.60 | 21% YoY | 1 |
Latest Reports
NEUTRAL
8-K
5/10
BioCardia received a Nasdaq extension to October 7, 2026, to regain compliance with the $2.5 million minimum stockholder
Jun 12, 2026
BEARISH
PRESS-RELEASE
7/10
BioCardia reported Q1 2026 EPS of -$0.21, missing the consensus estimate of -$0.18 by 16.7%. The company also disclosed
Jun 8, 2026
BULLISH
Press
8/10
BioCardia announced a positive outcome from its regulatory consultation with Japan's PMDA, which indicated that existing
Apr 20, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $150.8K | — |
| VANGUARD FIDUCIARY TRUST CO | $80.2K | — |
| CITADEL ADVISORS LLC | $76.7K | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $47.0K | — |
| COMMONWEALTH EQUITY SERVICES, LLC | $22.1K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | Altman Peter | BUY | $4.3K |
| May 20, 2026 | Altman Peter | BUY | $1.4K |
| May 19, 2026 | Altman Peter | BUY | $190.00 |
| May 18, 2026 | Altman Peter | BUY | $5.2K |
| May 15, 2026 | Altman Peter | BUY | $5.2K |
8 institutional holders with $397.6K total value (328,628 shares) as of 2026-Q1. Top holders: VANGUARD, VANGUARD, CITADEL.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 124,591 | $150.8K | 37.9% | — |
| 2 | VANGUARD FIDUCIARY TRUST CO | 66,270 | $80.2K | 20.2% | — |
| 3 | CITADEL ADVISORS LLC | 63,384 | $76.7K | 19.3% | — |
| 4 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 38,827 | $47.0K | 11.8% | — |
| 5 | COMMONWEALTH EQUITY SERVICES, LLC | 18,283 | $22.1K | 5.6% | — |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 13,900 | $16.8K | 4.2% | — |
| 7 | MORGAN STANLEY | 3,105 | $3.8K | 0.9% | DOUBLED +13286.7% |
| 8 | Vanguard Global Advisers, LLC | 268 | $324.00 | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 96,498 | 135,561 | +40.5% | $169.5K | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 12,884 | 96,498 | +649.0% | $124.5K | 2025-Q3 |
| UBS Group AG | DOUBLED | 4,179 | 10,740 | +157.0% | $13.9K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 30 | 4,016 | +13286.7% | $8.8K | 2024-Q4 |
1 unique insiders with 11 transactions. Net insider value: $29.8K ($29.8K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Altman Peter | President and CEO | BUY | 5,000 | $0.8500 | $4.3K |
| May 20, 2026 | Altman Peter | President and CEO | BUY | 1,500 | $0.9200 | $1.4K |
| May 19, 2026 | Altman Peter | President and CEO | BUY | 200 | $0.9500 | $190.00 |
| May 18, 2026 | Altman Peter | President and CEO | BUY | 5,700 | $0.9200 | $5.2K |
| May 15, 2026 | Altman Peter | President and CEO | BUY | 5,100 | $1.02 | $5.2K |
| Apr 29, 2026 | Altman Peter | President and CEO | BUY | 5,000 | $1.11 | $5.6K |
| Apr 21, 2026 | Altman Peter | President and CEO | BUY | 400 | $1.23 | $492.00 |
| Apr 20, 2026 | Altman Peter | President and CEO | BUY | 600 | $1.23 | $738.00 |
| Mar 25, 2026 | Altman Peter | President and CEO | BUY | 300 | $1.22 | $366.00 |
| Mar 24, 2026 | Altman Peter | President and CEO | BUY | 600 | $1.24 | $744.00 |
| Feb 4, 2026 | Altman Peter | President and CEO | BUY | 5,000 | $1.13 | $5.6K |
12 SEC filing reports analyzed. Sentiment: 4 bullish, 3 bearish, 2 mixed, 3 neutral. Avg impact: 5.7/10.
NEUTRAL
8-K
5/10
BioCardia received a Nasdaq extension to October 7, 2026, to regain compliance with the $2.5 million
Jun 12, 2026
BEARISH
PRESS-RELEASE
7/10
BioCardia reported Q1 2026 EPS of -$0.21, missing the consensus estimate of -$0.18 by 16.7%. The com
Jun 8, 2026
BEARISH
8-K
6/10
BioCardia raised $4.4 million via an at-the-market (ATM) offering, selling 3,509,604 shares at an av
Jun 8, 2026
BULLISH
8-K
6/10
BioCardia announced FDA confirmation that its ongoing CardiAMP Heart Failure II trial may support a
Jun 5, 2026
BULLISH
8-K
7/10
BioCardia announced that Japan's PMDA Consultation Record supports submission for regulatory approva
May 28, 2026
MIXED
8-K
6/10
BioCardia reported Q1 2026 financial results with a net loss of $2.3M ($0.21 per share), narrower th
May 15, 2026
MIXED
PRESS-RELEASE
6/10
BioCardia reported Q1 2026 EPS of -$0.21, missing consensus of -$0.17 by 23.5%, while revenue remain
May 15, 2026
NEUTRAL
PRESS-RELEASE
2/10
BioCardia announced it will report Q1 2026 financial results on May 15, 2026. The press release cont
May 11, 2026
BULLISH
8-K
6/10
BioCardia announced FDA alignment on two regulatory pathways for its Helix Transendocardial Delivery
May 8, 2026
NEUTRAL
8-K
2/10
BioCardia announced the allowance of a Japanese patent for its Heart3D Fusion Imaging software, whic
Apr 28, 2026
BEARISH
8-K
8/10
BioCardia received a Nasdaq delisting notice due to failing the $2.5 million minimum stockholders' e
Apr 15, 2026
BULLISH
8-K
7/10
BioCardia announced it has submitted clinical data to the FDA and requested a meeting to discuss an
Apr 2, 2026
BULLISH
8/10
BioCardia announced a positive outcome from its regulatory consultation with Japan's PMDA, which ind
Apr 20, 2026
BULLISH
8/10
BioCardia submitted clinical data from its CardiAMP HF trial to the FDA and plans to meet with the a
Apr 2, 2026
BEARISH
6/10
BioCardia reported its 2025 financial results, showing no revenue and a net loss of $8.2 million, wi
Mar 24, 2026
BULLISH
7/10
BioCardia announced that the FDA has accepted its pre-submission package for the Helix Transendocard
Mar 17, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$15.50 mean target
+1661.4% upside
Strong Buy (1.00)
$6.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $0.8800 |
| Target Low | $6.00 |
| Target Mean | $15.50 |
| Target Median | $15.50 |
| Target High | $25.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.19 | $-0.19 | $-0.19 | — | -5.6% | — | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.18 | $-0.18 | $-0.18 | 25.0% | -5.9% | — | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.76 | $-0.76 | $-0.76 | 38.2% | -7.0% | — | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-0.60 | $-0.60 | $-0.60 | 21.0% | -7.1% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.190 | |
| 7d ago | $-0.180 | -0.010 |
| 30d ago | $-0.180 | -0.010 |
| 60d ago | $-0.180 | -0.010 |
| 90d ago | $0.000 | -0.190 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 8, 2026
earnings
BioCardia Announces $4.4 Million Financing
<p align="center"><strong>Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currentl
Jun 5, 2026
other
FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF
<p align="left">SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia<sup>®</sup>, Inc. [Nasdaq: BCDA], a global leader in cellular and cel
May 15, 2026
earnings
BioCardia Reports First Quarter 2026 Business Highlights and Financial Results
<p>SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=_rOq6Ii3XAU6jdz3BWjXpaLhaSg2GEVBBtjUZS4fO
May 15, 2026
earnings_calendar
BCDA Q1 2026 Earnings Scheduled — 2026-05-15
May 13, 2026
earnings_calendar
BCDA Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
earnings_calendar
BCDA Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
earnings
BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026
<p align="left">SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=8GiDy3uLZOFLkUJ-mJderv52N5cV
May 8, 2026
other
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways
<p>SUNNYVALE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BioCardia<sup>®</sup>, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived ther
Apr 20, 2026
fda
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure
<p>SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- BioCardia<sup>®</sup>, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived th
Apr 2, 2026
fda
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure
<p align="left">SUNNYVALE, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- BioCardia<sup>®</sup>, Inc. [Nasdaq: BCDA], a global leader in cellular and ce
Mar 24, 2026
earnings
BioCardia Reports 2025 Business Highlights and Financial Results
<p>SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=6RAj97khnVvlySLJ0Polz7b-naQHgyBqQaUT2lo
Mar 24, 2026
earnings_calendar
BCDA Q4 2025 Earnings After Market Close — 2026-03-24
Mar 19, 2026
earnings
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
<p>SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=c62NH9mXsAktByrGGmRQS0D1n9Jqz2tHr9VD3Do
Mar 17, 2026
announcement
BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA
FDA Substantive Review and Meeting Scheduled for Early Q2 <pre>FDA Substantive Review and Meeting Scheduled for Early Q2</pre>
Mar 17, 2026
fda_pdufa
PDUFA: BCDA — Helix Transendocardial Delivery Catheter in intramyocardial therapeutic and diagnostic agent delivery — 2026-03-17
FDA target action date 2026-03-17 for BCDA (BioCardia, Inc.). Drug: Helix Transendocardial Delivery Catheter. Indication: intramyocardial therapeutic